- Prieto-Alhambra Group | Musculoskeletal Pharmaco- and Device epidemiology Research Group
- BisCK Research Group
M Sanni Ali
Senior Research Associate in Pharmacoepidemiology
Dr. M Sanni Ali studied Veterinary Medicine in 2000-2006 at Addis Ababa University (Ethiopia) and awarded "Doctor of Veterinary Medicine" with a "great distinction". He worked as a lecturer in Haramaya University (2006-2008) and Addis Ababa University (2008-2009). In the years 2009/11, he obtained an MSc degree in (Veterinary) Epidemiology and Economics (Utrecht University, the Netherlands) with "Cum Laude". In October 2014, he defended his PhD thesis entitled "Improving Propensity Score Methods in Pharmacoepidemiology" at Utrecht University.
His PhD topic was part of PROTECT (The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) project - a collaborative European project to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. He has worked on simulation and empirical studies evaluating methods in pharmaco-epidemiology such as propensity score, instrumental variable methods and marginal structural models.
He started working as a postdoctoral researcher at University Medical Centre Utrecht, The Netherlands since January 2014 on another IMI project - GetReal - a EU consortium aiming to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process.
He has experience in the design, analysis and interpretation of electronic medical records including data from the Netherlands (Mondriaan), Spain (BIFAP), United Kingdom (THIN and CPRD) and The USA (MarketScan) as well as simulation studies on validating and improving different statistical methods.
In February 2016, he joined Prieto-Alhambra Group | Musculoskeletal Pharmaco- and Device Epidemiology (Botnar Research Centre, NDORMS) as a Postdoctoral Research Assistant in Pharmacoepidemiology. He is working on a post-authorisation safety study through EU-ADR Alliance as well as a NIHR funded safety research.
Bezin J. et al, (2017), Pharmacoepidemiol Drug Saf, 26, 285 - 293
Ankarfeldt MZ. et al, (2017), Clin Epidemiol, 9, 19 - 30
Ankarfeldt MZ. et al, (2017), Clin Epidemiol, 9, 41 - 51
Assessment of Channelling Bias Among Initiators of Glucose Lowering Drugs - A Cohort Study
Ankarfeldt MZ. et al, (2016)
Ali MS. et al, (2016), Am J Clin Nutr, 104, 247 - 258